SCHOLAR ROCK HLDG DL-001(2QK)

Description: Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Cancer Biopharmaceutical Immune System Treatment Of Cancer Monoclonal Antibodies Cancer Immunotherapy Fibrosis Serious Diseases Checkpoint Inhibitor Clusters Of Differentiation Spinal Muscular Atrophy Pd 1 And Pd L1 Inhibitors Programmed Cell Death Protein 1 Neuromuscular Disorders Pd 1 Treatment Of Serious Diseases Cardiometabolic Disorders

---

Home Page: scholarrock.com

301 Binney Street
Cambridge, MA 02142
United States
Phone: 857 259 3860

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)